Molecular and clinical investigation of Iranian patients with friedreich ataxia.

Molecular and clinical investigation of Iranian patients with friedreich ataxia.. Salehi MH, Houshmand M, Aryani O, Kamalidehghan B, Khalili E., Iran Biomed J. 2014 Jan;18(1):28-33.

BIOMARKERS IN RARE NEUROMUSCULAR DISEASES

BIOMARKERS IN RARE NEUROMUSCULAR DISEASES . Chiara Scotton, Chiara Passarelli, Marcella Neri, Alessandra Ferlini; Experimental Cell Research, Available online 31 December 2013.

FULL TEXT PDF

Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease

Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease. NEW YORK and GERMANTOWN, Md., Dec. 31, 2013 /PRNewswire.

Agilis Biotherapeutics, LLC, a synthetic biology-based company focused on rare genetic diseases, and Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today an Exclusive Channel Collaboration (ECC) to develop DNA-based therapeutics for Friedreich's ataxia (FRDA), a rare genetic neurodegenerative disease.